Source comparison
TB-500 vs BPC-157 vs Growth Hormone Peptides
TB-500 Actin upregulation, angiogenesis, reduced fibrosis ~10 days Tendon strains, ligament sprains, muscle tears with vascular compromise 2x per week Animal models (horses, rodents); human case reports; no RCTs in athletes BPC-157 VEGF expression, collagen sy
This comparison does not assign a generated winner or score.
- TB-500
- Actin upregulation, angiogenesis, reduced fibrosis
- ~10 days
- Tendon strains, ligament sprains, muscle tears with vascular compromise
- 2x per week
- Animal models (horses, rodents); human case reports; no RCTs in athletes
- BPC-157
- VEGF expression, collagen synthesis, gut-brain axis modulation
- ~4 hours
- Acute muscle belly tears, GI issues, joint capsule injuries
- Daily (sometimes 2x daily)
- Rodent studies only; zero human clinical trials; mechanism plausible but unproven
- Ipamorelin + CJC-1295
- Growth hormone pulse stimulation, systemic IGF-1 elevation
- Ipamorelin: 2 hours; CJC-1295 (DAC): 6–8 days
- Systemic recovery, sleep quality, body composition
- Daily (ipamorelin); 2x per week (CJC w/ DAC)
- Phase II trials in growth hormone deficiency; off-label in athletics
- TB-500 is the only peptide in this comparison with published data in athletic species. BPC-157 has compelling rodent data but zero human trials and an unknown safety profile at commonly used doses. Growth hormone secretagogues target systemic recovery rather than localized tissue repair. Useful for overall training adaptation but not a substitute for direct injury intervention.
- Our honest assessment: if you're dealing with a specific tendon or ligament injury that's limiting training, TB-500 is the evidence-supported choice. If you're chasing generalized recovery or body composition changes, Real Peptides offers research-grade options across multiple peptide classes. But understand the difference between localized repair mechanisms and systemic growth signaling.